Research programme: non-alcoholic steatohepatitis therapeutics - Rubedo Life Sciences
Latest Information Update: 14 Feb 2024
At a glance
- Originator Rubedo Life Sciences
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Non-alcoholic steatohepatitis
Most Recent Events
- 04 Jan 2024 Early research in Non-alcoholic steatohepatitis in USA (unspecified route), prior to January 2024 (Rubedo Life Sciences, pipeline, January 2024)